CELG-RI Bristol-Myers Squibb Company Ce
NYSEHealthcareAs of 2026-07-10 15:07
Why CELG-RI matters now
Bristol-Myers Squibb Company Ce (CELG-RI) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.12 with -0.08% on the session and $241.8M in market capitalization.
The latest financial table shown here is Q4 2025, with revenue of $12.50B, net income of $1.09B, and EPS of $0.53. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield unavailable.
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $12.50B | $1.09B | $0.53 |
| FY 2025 | $48.19B | $7.05B | $3.46 |
| Q3 2025 | $12.22B | $2.20B | $1.08 |
| Q2 2025 | $12.27B | $1.31B | $0.64 |
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NYSE
Beta
-0.48
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.